NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 47 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $5 | -99.9% | 10,365 | 0.0% | 0.00% | – |
| Q3 2022 | $7,000 | -68.2% | 10,365 | -52.0% | 0.00% | – |
| Q2 2022 | $22,000 | -46.3% | 21,583 | 0.0% | 0.00% | – |
| Q1 2022 | $41,000 | -71.1% | 21,583 | -26.7% | 0.00% | – |
| Q4 2021 | $142,000 | -15.0% | 29,443 | +27.2% | 0.00% | – |
| Q3 2021 | $167,000 | -51.3% | 23,142 | -37.7% | 0.00% | – |
| Q2 2021 | $343,000 | +90.6% | 37,145 | +153.4% | 0.00% | – |
| Q1 2021 | $180,000 | -94.8% | 14,658 | -94.0% | 0.00% | -100.0% |
| Q4 2020 | $3,432,000 | -8.9% | 243,396 | -22.5% | 0.00% | -50.0% |
| Q3 2020 | $3,767,000 | -45.3% | 313,962 | -24.3% | 0.00% | -33.3% |
| Q2 2020 | $6,882,000 | +41.8% | 414,564 | -2.8% | 0.00% | 0.0% |
| Q1 2020 | $4,853,000 | -10.4% | 426,493 | -3.0% | 0.00% | +50.0% |
| Q4 2019 | $5,418,000 | +379.5% | 439,800 | +10.9% | 0.00% | – |
| Q3 2019 | $1,130,000 | – | 396,417 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 2,291,133 | $1,166,187 | 1.01% |
| Privium Fund Management (UK) Ltd | 117,200 | $59,655 | 0.04% |
| Redmile Group, LLC | 1,850,566 | $941,938 | 0.04% |
| Baker Brothers Advisors | 3,821,740 | $1,945,266 | 0.01% |
| Kynam Capital Management, LP | 120,764 | $61,469 | 0.01% |
| Sio Capital Management, LLC | 38,312 | $19,501 | 0.01% |
| SIMON QUICK ADVISORS, LLC | 46,856 | $23,850 | 0.00% |
| Tri Locum Partners LP | 10,248 | $5,000 | 0.00% |
| Endurance Wealth Management, Inc. | 20,000 | $10 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 75,000 | $38,175 | 0.00% |